ASSOCIATION OF CYP2D6 GENE POLYMORPHISMWITH FLUOXETINE INDUCED ADVERSE REACTIONSIN PATIENTS WITH MAJOR DEPRESSION

This study rigorously explores the intricate relationship between geneticpolymorphisms within the CYP2D6 gene, and the manifestation of adverse drug reactions induced by fluoxetine in individuals diagnosed with MDD. MDD represents a debilitating and challenging condition with a multifaceted etiology, encompassing genetic predisposition as a contributing factor. Nevertheless, a frequently recommended antidepressant that is the response to fluoxetine differs notably amongpeople. This variability results in the attribution to genetic variations in the gene encoding an enzyme CYP2D6 that is essential for the metabolism of fluoxetine. In this study, we intend to delve into the connection among CYP2D6 gene polymorphisms and adverse drug reactions to fluoxetine as well as evaluate the effect on productiveness of fluoxetine in MDD, and to inquire into their impact on the antidepressant effect of fluoxetine. The study also shows that there is polymorphic CYP2D6 alleles that is connected to an elevated probability of adverse drug reactionsto the fluoxetine, lessening the treatment productiveness, and low enhancement in the depressive symptoms. So, to address this issue the study delves into a sample of MDD patients, encompassing the clinical scales, and genetic testing to evaluate the role of CYP2D6 gene variations in fluoxetine response. The outcomes of this research arewide-ranging. This study also contributes to the evolving field of pharmacogenomics in psychiatry that facilitates the personalized treatment methods for MDD patients. Adverse reactions can be reduced, productivity can be increased, and patient safety can be improved by changing medication choices and doses based on geneticinformation. So, this research thus inquiries into enhance the standard of life and welfare of individuals who are struggling with this MDD.